OTCPicks.com’s Daily Small Cap and Microcap Newsletter presents a range of the hottest small cap stocks on trading on the OTC and OTCBB markets. In addition to our Newsletters, OTCPicks.com is quickly becoming the premier community destination for small cap and microcap traders to meet up and discuss their top stock picks. Visit http://www.otcpicks.com/microcap.htm today to join this growing community.
Our Stocks to Watch tomorrow include Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ), Ingen Technologies Inc. (OTC: IGNT), MDRNA Inc. (Nasdaq: MRNA), STAAR Surgical Co. (Nasdaq: STAA) and Cascadia Investments Inc. (OTC: CDIV). Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
JAZZ PHARMACEUTICALS INCORPORATED (NASDAQ: JAZZ) "Up 2.00% on Tuesday" Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry.
INGEN TECHNOLOGIES INCORPORATED (OTC: IGNT) "Up 314.29% on Tuesday" Ingen Technologies, Inc. is the leading world manufacturer of gravity-independent in-line oxygen flow meter products and services related to pulmonary and respiratory therapeutic hospital and home oxygen therapy. The company has adopted quality improvement (QI) initiatives throughout all areas of operations. Ingen Technologies is registered with the Food & Drug Administration, and licensed in good standing with the Department of Health Services. Headquartered in Yucaipa, California, the company distributes its respiratory products in North America, Asia and European Communities, and its operations provide sales, logistics, billing and collections. Supported by corporate functions such as Finance, Information Services, Human Resources, Legal and Contract Services, Ingen Technologies division and regional business units are able to respond quickly to customer and patient needs.
MDRNA INCORPORATED (NASDAQ: MRNA) "Up 75.32% on Tuesday" MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in key therapeutic areas including oncology, metabolic disorders and inflammation. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company.
STAAR SURGICAL COMPANY (NASDAQ: STAA) "Up 46.30% on Tuesday" STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 50 countries. Collamer® is the brand name for STAAR's proprietary collagen copolymer lens material.
CASCADIA INVESTMENTS INCORPORATED (OTC: CDIV) "Up 71.43% on Tuesday" Cascadia Investments, Inc. is a publicly-traded, real estate development company operating in the Pacific Northwest. The company's principal objective is to create equity and long-term earnings growth through the acquisition and development or renovation of undervalued and foreclosed real estate.
About OTCPicks.com
OTCPicks.com is fast becoming the premier Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Research Reports authored by our financial writers. We publish our Daily Market Movers Digest Newsletter to opt-in investor members. OTCPicks.com presents the latest information for the discerning small cap and microcap investor. The site features informative articles on microcap investing, the top penny stock picks, and a wealth of small cap research on vertical markets. To feature a company on OTCPicks.com, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Forward-Looking Statement:
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release. OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.
